These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28572128)

  • 1. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    van der Werf MJ; Ködmön C; Catchpole M
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572128
    [No Abstract]   [Full Text] [Related]  

  • 2. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Heldal E; Van Deun A; Chiang CY; Rieder HL
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572127
    [No Abstract]   [Full Text] [Related]  

  • 3. Multidrug-resistant tuberculosis and migration to Europe.
    van der Werf MJ; Hollo V; Ködmön C
    Clin Microbiol Infect; 2017 Aug; 23(8):578-579. PubMed ID: 28232165
    [No Abstract]   [Full Text] [Related]  

  • 4. Fighting drug-resistant tuberculosis in eastern Europe.
    Drobniewski F; Ehsani S; Dara M
    Lancet Infect Dis; 2017 Jul; 17(7):691-692. PubMed ID: 28653631
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to Letter to the Editor by M. van der Werf, V. Hollo and C. Ködmön concerning 'Multidrug-resistant tuberculosis and migration to Europe'.
    Hargreaves S; Lönnroth K; Nellums LB; Olaru ID; Nathavitharana RR; Norredam M; Friedland JS
    Clin Microbiol Infect; 2017 Aug; 23(8):580. PubMed ID: 28257900
    [No Abstract]   [Full Text] [Related]  

  • 6. Multidrug-resistant tuberculosis in Europe, 2010-2011.
    Günther G; van Leth F; Alexandru S; Altet N; Avsar K; Bang D; Barbuta R; Bothamley G; Ciobanu A; Crudu V; Davilovits M; Dedicoat M; Duarte R; Gualano G; Kunst H; de Lange W; Leimane V; Magis-Escurra C; McLaughlin AM; Muylle I; Polcová V; Pontali E; Popa C; Rumetshofer R; Skrahina A; Solodovnikova V; Spinu V; Tiberi S; Viiklepp P; Lange C;
    Emerg Infect Dis; 2015 Mar; 21(3):409-16. PubMed ID: 25693485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The worldwide epidemic of multidrug-resistant tuberculosis.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2011 May; 11(5):333. PubMed ID: 21530885
    [No Abstract]   [Full Text] [Related]  

  • 8. Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Barry PM; Lowenthal P; True L; Henry L; Schack G; Wendorf K; Flood J; Shah N
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1488-1489. PubMed ID: 28665681
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    van Leth F; Günther G; Hoffmann H; Lange C;
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1489-1490. PubMed ID: 28715229
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Varaine F; Guglielmetti L; Mitnick CD
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1490-1491. PubMed ID: 28715258
    [No Abstract]   [Full Text] [Related]  

  • 11. Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope.
    Prasad R; Gupta N; Banka A
    Indian J Med Res; 2017 Sep; 146(3):301-303. PubMed ID: 29355135
    [No Abstract]   [Full Text] [Related]  

  • 12. Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.
    Van Deun A; Chiang CY
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572126
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Chesov D; Ciobanu N; Lange C; Heyckendorf J; Crudu V
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025881
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis.
    Sougakoff W
    Clin Microbiol Infect; 2011 Jun; 17(6):800-5. PubMed ID: 21682800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children?
    Shah I
    Indian Pediatr; 2017 Feb; 54(2):160. PubMed ID: 28285296
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap.
    Nunn A; Tweed C
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1418-1419. PubMed ID: 27725060
    [No Abstract]   [Full Text] [Related]  

  • 17. Tuberculosis in migrants from 106 countries to Italy, 2008-2014.
    Fattorini L; Mustazzolu A; Borroni E; Piccaro G; Giannoni F; Cirillo DM;
    Eur Respir J; 2016 Apr; 47(4):1273-6. PubMed ID: 26846829
    [No Abstract]   [Full Text] [Related]  

  • 18. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
    Lange C; Duarte R; Fréchet-Jachym M; Guenther G; Guglielmetti L; Olaru ID; Oliveira O; Rumetshofer R; Veziris N; van Leth F;
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1029-1031. PubMed ID: 27685538
    [No Abstract]   [Full Text] [Related]  

  • 19. Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen.
    Achar J; Berry C; Herboczek K; Parpieva N; Tillyashaykhov MN; Tigay ZN; Khamraev A; Velivela K; Seddon JA; du Cros P
    Emerg Infect Dis; 2015 Nov; 21(11):2105-6. PubMed ID: 26488556
    [No Abstract]   [Full Text] [Related]  

  • 20. Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?
    Tiberi S; D'Ambrosio L; Centis R; Migliori GB
    Int J Infect Dis; 2017 Dec; 65():133-134. PubMed ID: 29122690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.